<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Coxiella burnetti – Q fever</h1><h2 class="text-xl font-semibold mt-6 mb-3"><strong>1. Overview &amp; Taxonomy</strong></h2><p class="ml-4 mb-2">Small, pleomorphic, <strong>Gram-negative coccobacillus</strong>.<strong>Obligate intracellular</strong> (replicates in acidic phagolysosomes of host cells, esp. macrophages).Two morphologic variants:<strong>Small Cell Variant (SCV)</strong> — metabolically inactive, environmentally resistant; survives months–years in dust, wool, milk.<strong>Large Cell Variant (LCV)</strong> — metabolically active.<strong>Non-motile</strong>, no flagella.<strong>Antigenic phases</strong> (LPS variation):<strong>Phase I</strong> — smooth LPS, virulent, found in nature.<strong>Phase II</strong> — rough LPS, avirulent, seen after in vitro passage.<strong>Reservoirs</strong>: sheep, goats, cattle (primary); also cats, dogs, wild mammals, birds, ticks.<strong>Transmission</strong>:Aerosolised particles from birth products, urine, faeces, milk.Raw milk ingestion possible (less common).Very low infectious dose (~1 organism).Rare human-to-human spread.<strong>Epidemiology</strong>: Worldwide; UK notifiable disease.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>2. Laboratory Microbiology</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>A) Safety</strong></h3><p class="ml-4 mb-2"><strong>Hazard Group 3</strong> — highly infectious via aerosols. All culture or manipulation in <strong>BSL-3</strong> containment.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>B) Growth &amp; Culture</strong></h3><p class="ml-4 mb-2">No growth on routine bacteriological media.Requires <strong>eukaryotic host cells</strong>: embryonated eggs, cell lines (e.g., Vero, L929, HeLa), or lab animals.Culture performed only in reference labs (never routine).</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>C) Staining</strong></h3><p class="ml-4 mb-2">Gram stain: faint Gram-negative coccobacilli (often not seen).<strong>Gimenez stain</strong>: organisms stain red against green background.<strong>Stamp stain</strong> (modified Ziehl-Neelsen): organisms stain red.<strong>Immunohistochemistry (IHC)</strong>: detects antigen in tissue (valve, liver) — useful in culture-negative IE.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>D) Molecular Diagnostics</strong></h3><p class="ml-4 mb-2">PCR is <strong>first-line in early acute infection</strong> (before seroconversion).Best specimens:EDTA blood or serum in early acute (&lt;2 wks).Tissue from valves, vascular grafts, aneurysms, liver biopsy in chronic disease.Limitations:Sensitivity declines after 2 weeks in acute infection or after antibiotics.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>E) Serology (IFA = reference standard)</strong></h3><p class="ml-4 mb-2">Measures IgG/IgM to Phase I and II antigens.<strong>Acute Q fever</strong>:High <strong>Phase II</strong> IgG ± IgM; Phase I low or absent early.<strong>Chronic Q fever</strong>:High <strong>Phase I</strong> IgG (≥1:800; lab-specific cut-off), often high Phase II IgG too.Paired sera (2–3 weeks apart) may be needed — early samples can be negative.Cross-reactions: occasional low-level with <em>Legionella</em>, <em>Bartonella</em>, <em>Chlamydophila</em>.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>G) Antimicrobial Susceptibility Testing</strong></h3><p class="ml-4 mb-2">Not routine — obligate intracellular nature prevents standard MIC testing.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>3. Clinical Syndromes</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>A) Acute Q Fever</strong></h3><p class="ml-4 mb-2">Incubation: ~2–3 weeks.Presentations:Asymptomatic (≈50%).Abrupt<strong> flu-like illness</strong>: fever, sweats, headache, myalgia.<strong>Atypical pneumonia</strong>: non-productive cough, patchy infiltrates.<strong>Hepatitis</strong>: fever, hepatomegaly, raised transaminases ± jaundice.Complications: meningoencephalitis, myocarditis, pericarditis.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>B) Chronic Q Fever</strong></h3><p class="ml-4 mb-2">Occurs in &lt;5% of infections; months–years after acute phase.Risk factors: pregnancy, immunosuppression, valvular/vascular abnormalities, prosthetic valves/grafts.Most common form: <strong>culture-negative endocarditis</strong>.Others: infected aneurysm, vascular graft infection, chronic hepatitis, osteomyelitis.High mortality untreated.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>C) Q Fever in Pregnancy</strong></h3><p class="ml-4 mb-2">Higher maternal and fetal risks: miscarriage, stillbirth, preterm delivery.Chronic infection risk increased.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>4. Diagnosis – Practical Summary</strong></h2><table><tr><td><p><strong>Scenario</strong></p></td><td><p><strong>Best test(s)</strong></p></td></tr><tr><td><p>Early acute (&lt;14 d)</p></td><td><p>PCR on EDTA blood ± serum</p></td></tr><tr><td><p>Acute (&gt;14 d)</p></td><td><p>Serology (rise in Phase II IgG/IgM)</p></td></tr><tr><td><p>Chronic Q fever</p></td><td><p>Serology: high Phase I IgG ≥1:800 ± PCR on tissue</p></td></tr><tr><td><p>BCNIE / vascular</p></td><td><p>Coxiella + Bartonella serology; PCR on valve if available</p></td></tr></table><h2 class="text-xl font-semibold mt-6 mb-3"><strong>5. Treatment</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>A) Acute Q Fever</strong></h3><p class="ml-4 mb-2">Adults: <strong>Doxycycline 100 mg bd × 14 days</strong> (7 days may suffice for uncomplicated pneumonia; use 14 days if hepatitis).Pregnancy: <strong>Co-trimoxazole 160/800 mg bd</strong> until delivery (stop ~32–36 wks to avoid folate antagonism).</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>B) Chronic Q Fever (IE/vascular infection)</strong></h3><p class="ml-4 mb-2"><strong>Doxycycline 100 mg bd + Hydroxychloroquine 200 mg tds</strong>Duration: ≥18 mo (native valve), ≥24 mo (prosthetic/graft).Monitor HCQ levels (target 0.8–1.2 µg/ml) and retinal toxicity.Follow Phase I IgG titres — falling titres suggest cure.If HCQ contraindicated: doxycycline + fluoroquinolone (less effective).</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>C) Post-Exposure Prophylaxis</strong></h3><p class="ml-4 mb-2">For high-risk exposures (e.g., pregnant lab worker): <strong>Doxycycline 100 mg daily × 5–7 days</strong> within 8–12 days post-exposure.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>6. Prevention &amp; Control</strong></h2><p class="ml-4 mb-2">No UK-licensed human vaccine (Q-Vax in Australia; whole-cell inactivated; requires pre-vaccine screening).Animal control: manage birthing products, pasteurise milk, vaccinate animals in endemic areas.Lab: strict BSL-3 containment for culture/high-risk specimens.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>7. Exam Pearls</strong></h2><p class="ml-4 mb-2">Always request <strong>Coxiella + Bartonella serology</strong> in BCNIE.Chronic Q fever = <strong>high Phase I IgG</strong> — a <strong>major Duke-ISCVID criterion</strong> for IE.PCR from blood is <strong>early-phase only</strong>; tissue PCR preferred in chronic disease.Pregnancy: treat until delivery even if asymptomatic (to reduce fetal loss).Phase I vs Phase II serology differentiation is a favourite exam question.Extremely infectious: single organism can cause disease; lab safety is critical.</p>
</div>